The post Step Pharma announces first patient dosed in a phase 1 trial of dencatistat for patients with solid tumours appeared first on Step Pharma ..read more

Press Release St. Genis-Pouilly, France, 24 July 2024 Step Pharma, the world leader in CTPS1 inhibition for the targeted treatment of cancer, today announces the publication in the August edition of Haematologica of preclinical data from the University of Nantes (CRCI2NA) further supporting the therapeutic activity of Step’s highly selective CTPS1 inhibitors in the treatment of blood cancers. The therapeutic activity was observed for mantle cell lymphoma (MCL), including difficult-to-treat in vitro and in vivo models. Furthermore, Step Pharma’s CTPS1 inhibitors show significant synerg ..read more

Press Release St. Genis-Pouilly, France, 25 June 2024 Step Pharma, the global leader in CTPS1 inhibition for targeted cancer treatment, today announced that its lead asset dencatistat (STP938), a first-in-class selective CTPS1 inhibitor, has cleared an investigational new drug (IND) application by the US Food and Drug Administration (FDA), enabling Step Pharma to progress dencatistat into a Phase 1 clinical trial for patients with solid tumours, anticipated to start in Q3 2024. The open label trial will evaluate the safety, tolerability and pharmacokinetics of dencatistat in adults li ..read more

Press Release St. Genis-Pouilly, France, 30 May 2024 Step Pharma, the global leader in CTPS1 inhibition for targeted cancer treatment, today announced it has received an issue notification from the United States Patent and Trademark Office (USPTO), indicating the grant of a new US patent, and that the International Nonproprietary Names (INN) expert committee has approved the name “dencatistat” for the Company’s lead compound STP938. The patent, US Patent No 11,987,573, covers one of the key compounds within the Company’s extensive portfolio of CTPS1 inhibitor assets. This patent issue ..read more

Over the years, there have been a number of significant advances in the treatment and management of cancer.   However, cancer has been, and continues to be, one of the most challenging diseases to solve. Despite decades of research dedicated to the search for cures, cancer is currently the world’s biggest killer, responsible for the deaths of around 10 million people globally, young and old, every year. For this reason, there is a need to explore new ideas and new concepts. With 18 million new cases of cancer worldwide reported in 2020, and 10 million deaths, there is a need to explo ..read more

Press Release St. Genis-Pouilly, France, 09 March 2023 Step Pharma, the world leader in CTPS1 inhibition for the targeted treatment of cancer, today announces that the European Patent Office (”EPO”) has granted patent EP3870574, which covers key compounds in the Company’s broad portfolio of CTPS1 inhibitor assets. The granting of this patent strengthens the Company’s patent portfolio covering its CTPS1 inhibitor assets, which is currently protected by a range of published and unpublished patent families. By targeting CTPS1, an enzyme that catalyses a rate-limiting step in pyrimidine s ..read more

Press Release St. Genis-Pouilly, France, 3 November 2022 Concr’s proprietary statistical modelling, which uses cosmology methods, will identify biomarkers to help select patients most likely to respond to Step Pharma compounds targeting cytidine triphosphate synthase 1 (CTPS1). St. Genis-Pouilly, France and London, UK, 07 December 2022 – Step Pharma, the world leader in CTPS1 inhibition for the targeted treatment of cancer, and Concr, a techbio company with a statistical learning-powered biomarker prediction engine, today announced a partnership to identify biomarkers to improve thera ..read more

Press Release St. Genis-Pouilly, France, 24 October 2022 Potential first-in-class targeted treatment for relapsed/refractory T cell and B cell lymphomas Step Pharma, the world leader in CTPS1 inhibition for the targeted treatment of cancer, announces today that the first patient has been successfully dosed with STP938, in a Phase 1/2 trial in adult subjects with relapsed/refractory B cell and T cell lymphomas. The dose-escalation part of the open label, non-randomised Phase 1/2 trial comprises multiple cohorts dosed with STP938, administered as an oral monotherapy, ascending in a step ..read more

Philip Beer, Chief Scientific Officer at Step Pharma, who is also the Chair of the Genomics Working Group of the British In Vitro Diagnostics Association (BIVDA), provides his perspectives on the recently published report titled “Leveraging partnerships to realise the UK’s potential in genomics” which focuses on the UK genomics landscape and patient access to genomic testing. Philip details the reasons he got involved in BIVDA’s Genomics Working Group and the difference genomic testing can make in cancer treatment. Genetic testing to identify DNA changes in cancer samples has the potential ..read more

Press Release St. Genis-Pouilly, France, 10 May 2023 Step Pharma, the world leader in CTPS1 inhibition for the targeted treatment of cancer, today announces that members of its management team will be participating at a number of conferences in May and June 2023. By targeting CTPS1, an enzyme that catalyses a rate-limiting step in pyrimidine synthesis, Step Pharma has unlocked the ability to selectively inhibit the de novo pyrimidine synthesis pathway, enabling a highly selective treatment of cancer. 23rd Bio€quity Europe, Dublin, Ireland, 15-16 May & 22-23 May Digital Partnering ..read more